Navigation Links
Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results
Date:10/27/2011

SAN DIEGO, Oct. 27, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced it will report third quarter 2011 financial results after the NASDAQ Global Market closes on November 3.  The Company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the financial results and highlights for the third quarter as well as provide a corporate update.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

The conference call may be accessed by dialing (877) 280-7280 for domestic callers and +1 (678) 825-8232 for international callers. Please specify to the operator that you would like to join "Optimer's Financial Results Call."  The conference call will be webcast live under the Investors section of Optimer's website at www.optimerpharma.com, where it will be archived for 30 days following the call.  Please connect to Optimer's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.  

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has developed and commercialized DIFICID™ (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adults 18 years of age or older with Clostridium difficile-associated diarrhea (CDAD). Optimer has filed a marketing authorization application with the European Medicines Agency for fidaxomicin. Optimer's clinical pipeline includes Pruvel™, a product in the fluoroquinolone class of antibiotics that has completed Phase 3 trials as a t
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
3. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
6. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
7. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
8. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
9. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
10. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
11. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Freeslate, Inc ., the leading provider ... Limited, one of India’s top five pharmaceutical companies, has ... for high throughput solid form screening. , ... wide range of quality, affordable generic and branded formulations ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have ... at 2pm EST (11am PST), “Natural Language Processing: Converting ... how technology can turn raw, heterogeneous data into actionable ... The online webinar will last approximately one hour. , ...
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an ... products to serve the wound care market. , Free ... Alliqua was restructured with a seasoned management team and ...
(Date:1/14/2014)... In recent years, growing suspicion about ... product development and promotion has led to unprecedented levels ... by concerns about the insidious impact of commercialization of ... fines to the world’s biggest pharmas for illegal marketing ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... , , HONG KONG, Dec. 31 /PRNewswire-Asia-FirstCall/ ... CO ), China,s leading provider of cord blood ... storage services, today announced that the underwriters of its recent ... their over-allotment option, which will result in the issuance of ...
... NORTH BILLERICA, Mass., Dec. 29 Seahorse Bioscience, Inc., leader ... bioenergetics, announced that TheScientist magazine cited their XF96 ... A panel of scientific experts assembled by TheScientist ... the two energy pathways of the cell in a microplate, ...
... , EMERYVILLE, Calif., Dec. 29 ... of results from its study on the anti-tumor mechanism of ... International Journal of Cancer , describe the potential molecular ... BN107 on estrogen receptor negative (ER-) breast cancer cells. , ...
Cached Biology Technology:China Cord Blood Corporation Announces Partial Exercise of Over-Allotment Option 2China Cord Blood Corporation Announces Partial Exercise of Over-Allotment Option 3TheScientist Awards Seahorse XF96 Analyzer a Top Ten Innovation for 2009 2Bionovo Announces Publication Describing First Novel Dual mTOR Inhibitor, BN107, for the Treatment of Breast Cancer 2Bionovo Announces Publication Describing First Novel Dual mTOR Inhibitor, BN107, for the Treatment of Breast Cancer 3
(Date:4/20/2014)... and pancreatic cancers also promote drug-resistance and ultimately spur ... Diego School of Medicine have discovered a molecule, or ... that appears responsible for inducing tumor metastasis by enhancing ... The findings, published in the April 20, 2014 online ... to new therapeutic opportunities for reversing drug resistance in ...
(Date:4/18/2014)... in Peru found that 28 percent of the ... falsified. Many pills released the active ingredient too ... batch had no active ingredient at all. ... the Georgia Institute of Technology developed a sophisticated ... counterfeit drugs and then characterize their chemical composition. ...
(Date:4/18/2014)... NC Ancient DNA adds a twist to the story ... to be published April 21 in the journal Proceedings ... from the bones of chickens that lived 200-2300 years ago ... ago domestic chickens may have looked far different from the ... of the traits we associate with modern domestic chickens -- ...
Breaking Biology News(10 mins):Cancer stem cells linked to drug resistance 2Counterfeit contraceptives found in South America 2Counterfeit contraceptives found in South America 3Ancient DNA offers clues to how barnyard chickens came to be 2
... Jianmin Cui was handed a puzzling clue to the structure ... five years. Scientists at the Cleveland Clinic Foundation in ... epilepsy, sudden attacks of involuntary movement or both, a syndrome ... the DNA of the 16 family members who had inherited ...
... are fostering development of a new generation of vaccines, ... potentially deadly bacteria in any future bioterrorist incident. That,s ... on medical technology to combat the anthrax threat. It ... . In the article, Dimitrios Bouzianas notes ...
... Scientists are reporting that particle size affects the toxicity ... smaller than 100 nanometers are slightly more toxic to colon ... toxic than equivalent amounts of soluble zinc, and direct particle ... study is in ACS, Chemical Research in Toxicology , ...
Cached Biology News:Solving the puzzle of the BK ion channel 2Solving the puzzle of the BK ion channel 3Solving the puzzle of the BK ion channel 4Solving the puzzle of the BK ion channel 5New medical weapons to protect against anthrax attacks 2
... for your specific applications and built on ... platform. Thousands of customer specified sequences can ... provide assistance with custom sequence design. These ... comprehensive Custom DNA Microarray Service. ...
... designed for DNA aptamer screening and binding ... powerful Paraflo microfluidic on-chip synthesis platform. These ... comprehensive DNA/RNA Aptamer Microarray Service. ... Microarray contains greater than 1500 known aptamer ...
... for DNA aptamer screening and binding optimization ... Paraflo microfluidic on-chip synthesis platform. Thousands of ... and LC Sciences can provide assistance with ... as part of our comprehensive DNA/RNA Aptamer ...
... (GST) is commonly used as a fusion ... (1). The GSTTag sequence has been reported ... cases the solubility of its fusion partners. ... form, GSTTag fusion proteins can be purified ...
Biology Products: